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At A Glance
What is the current scientific knowledge on this subject?
Considerable variation in hospital mortality has been described for patients admitted to 
the intensive care unit with coronavirus disease 2019 (COVID-19). However, the factors 
that explain these differences remain unclear.
What does this study add to the field?
In this study of 4,019 patients in 70 hospitals, we found significant interhospital variation 
in mortality for critically ill patients with COVID-19. This hospital-level variation was 
mostly explained by hospital-level socioeconomic status, strain, and physiologic 
differences, although individual mortality was driven mostly by patient-level factors.
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ABSTRACT
Rationale: Variation in hospital mortality has been described for coronavirus disease 
2019 (COVID-19), but the factors that explain these differences remain unclear.
Objective: Our objective was to utilize a large, nationally representative dataset of 
critically ill adults with COVID-19 to determine which factors explain mortality variability.
Methods: In this multicenter cohort study, we examined adults hospitalized in intensive 
care units with COVID-19 at 70 United States hospitals between March and June 2020. 
The primary outcome was 28-day mortality. We examined patient-level and hospital-
level variables. Mixed-effects logistic regression was used to identify factors associated 
with interhospital variation. The median odds ratio (OR) was calculated to compare 
outcomes in higher- vs. lower-mortality hospitals. A gradient boosted machine algorithm 
was developed for individual-level mortality models.
Measurements and Main Results: A total of 4,019 patients were included, 1537 (38%) 
of whom died by 28 days. Mortality varied considerably across hospitals (0-82%). After 
adjustment for patient- and hospital-level domains, interhospital variation was 
attenuated (OR decline from 2.06 [95% CI, 1.73-2.37] to 1.22 [95% CI, 1.00-1.38]), with 
the greatest changes occurring with adjustment for acute physiology, socioeconomic 
status, and strain. For individual patients, the relative contribution of each domain to 
mortality risk was: acute physiology (49%), demographics and comorbidities (20%), 
socioeconomic status (12%), strain (9%), hospital quality (8%), and treatments (3%). 
Conclusion: There is considerable interhospital variation in mortality for critically ill 
Page 4 of 53
 AJRCCM Articles in Press. Published April 23, 2021 as 10.1164/rccm.202012-4547OC 
 Copyright © 2021 by the American Thoracic Society 
patients with COVID-19, which is mostly explained by hospital-level socioeconomic 
status, strain, and acute physiologic differences. Individual mortality is driven mostly by 
patient-level factors.
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INTRODUCTION
As of April 2021, coronavirus disease 2019 (COVID-19) has killed more than 500,000 
people in the United States.1 When patients develop severe disease, they are typically 
transferred to the intensive care unit (ICU), which provides more intensive monitoring 
along with potentially life-saving critical care therapies such as mechanical ventilation, 
vasoactive agents, and extracorporeal membrane oxygenation.2,3 Studies conducted 
prior to the pandemic demonstrated that outcomes of critically ill patients vary across 
hospitals, which may relate to differences in patient characteristics and the quality of 
care provided at different hospitals.4 Emerging data suggest similar variability in 
outcomes across hospitals for critically ill patients admitted with COVID-19.5-8 The 
causes of this variability are unclear and could include differences in demographics, 
comorbidities, physiologic severity of illness, socioeconomic status, resource strain, 
hospital quality, and treatments provided. It is also unknown how each of these domains 
impacts mortality risk for individual patients. A better understanding of the patient- and 
hospital-level factors impacting death could lead to insights into the reasons for the wide 
variation in reported outcomes, the determinants of individual patient outcomes, and 
improved healthcare delivery.
Our objective was to utilize a large, nationally representative dataset of critically ill 
adults with COVID-19 to determine which factors explain the variability in mortality at 
both the hospital and the patient level. To do this, we linked detailed patient information 
with hospital-level data and then explored how different domains explained variations in 
28-day mortality. 
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METHODS
Study design, setting, and population
We utilized the multicenter Study of the Treatment and Outcomes in Critically Ill Patients 
with COVID-19 (STOP-COVID) database, a cohort study of 5,154 patients with COVID-
19 admitted to ICUs across the United States (Table E1 in the Supplementary 
Appendix lists the sites included in this study).5 We included consecutive adults (age 
≥18 years) admitted to the ICU with laboratory-confirmed COVID-19 admitted between 
March 4 and June 29, 2020. Patients were followed until the first of hospital discharge, 
death, or at least 28 days after ICU admission. Patients transferred to the ICU from 
other hospitals, admitted to a hospital not linked to the Medicare Hospital Compare 
ratings, or admitted to a hospital with less than 10 COVID-19 ICU admissions in the 
dataset were excluded. A sensitivity analysis was performed by including patients 
transferred from outside hospitals. The study was approved by Institutional Review 
Boards at each site with a waiver of informed consent.
Data collection and outcome
Manual chart review was performed at each site using a standardized case report form, 
as previously described.5 Patient-level data collected included admission day, 
demographic information, comorbidities, vital signs on ICU admission, laboratory 
values, medications, non-medication treatments, and organ support in the first two 
weeks of ICU admission, and outcomes, including in-hospital mortality. The STOP-
COVID dataset also included what type of ICU bed the patient was admitted to (e.g., 
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medical-surgical), whether the patient was admitted to a COVID-specific ICU or surge 
unit, and the number of ICU beds at each hospital prior to the COVID-19 pandemic.
Additional hospital-level variables were collected by linking each study hospital to data 
from the following sources: the American Hospital Association Annual Survey 2020 
database for hospital strain and capacity variables; the 2017 Medicare Hospital 
Compare ratings for hospital quality ratings; the Healthcare Cost Report Information 
System; and the 2015 American Community Survey for socioeconomic status data, 
which incorporates information from communities surrounding each hospital by utilizing 
a previously described methodology (Table E2 in the Supplementary Appendix).9-11 
Furthermore, time-varying variables describing hospital-level strain were collected from 
the STOP-COVID dataset (i.e., number of other patients with COVID-19 currently in the 
ICU at a given hospital when a patient was admitted) and from publicly available data 
on the number of new COVID-19 cases from the past 30 days for the county where 
each hospital was located.1
The primary outcome of the study was in-hospital death within 28 days of ICU 
admission. If a patient was discharged alive before day 28, they were assumed to be 
alive at day 28. This assumption was confirmed in a sample of patients in a previous 
study.5 A sensitivity analysis was performed using in-hospital mortality as the outcome.
Statistical analysis
Explanatory variables were categorized into six domains, including three patient-level 
and three hospital-level domains. The individual variables and domains were chosen a 
priori based on prior literature and availability. Patient-level domains included: acute 
Page 8 of 53
 AJRCCM Articles in Press. Published April 23, 2021 as 10.1164/rccm.202012-4547OC 
 Copyright © 2021 by the American Thoracic Society 
physiology and severity of illness in the first 48 hours of ICU admission (e.g., vital signs, 
laboratory values, ventilatory support, number of vasopressors, and renal replacement 
therapy); demographics and comorbidities (e.g., age, sex, race, body mass index, 
smoking status, and pre-existing conditions); and treatments provided in the first 48 
hours of ICU admission (e.g., corticosteroids, remdesivir, tocilizumab, prone position 
ventilation). Hospital-level treatment intensity was also included as a variable in the 
treatment domain by calculating the percentage of mechanically ventilated patients with 
a PaO2/FiO2 ratio<150 who were treated with extracorporeal membrane oxygenation, 
inhaled pulmonary vasodilators, tocilizumab, prone positioning, or neuromuscular 
blockade. Hospital-level domains included: socioeconomic factors at the hospital level 
(e.g., % high school diploma, % unemployed, % English speaking, % travel to work >45 
minutes); hospital strain (e.g., number of ICU beds prior to COVID-19, time-varying 
number of ICU beds filled with COVID-19 patients, whether the patient was admitted to 
a COVID-specific ICU or surge unit, total number of medical-surgical beds, ICU 
occupancy rate pre-pandemic, number of hospital beds in the county, number of 
COVID-19 cases in the county from the prior 30 days); and hospital quality scores 
(mortality, readmission, safety, timeliness, patient experience, and effectiveness). ICU 
admission day was used to create a variable that denotes the “days since study start” 
that a patient was admitted to the ICU, which was assigned to each patient to account 
for possible longitudinal changes in hospital quality.12 The full variable list for each 
domain, along with additional descriptions, is provided in Table E2 in the 
Supplementary Appendix. Missing values were imputed using bagged forests from the 
caret package in R, which builds ensembles of decision trees, with each tree fit to a 
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randomly selected bootstrapped sample of the dataset, using non-missing variables to 
impute missing variables (see Table 1 for the amount of missing data for each variable). 
This approach has the advantage of automatically modeling non-linearities and 
interactions that may be important for accurate variable imputation.13 Comparisons 
between patients who survived vs. died within 28 days were made for all study variables 
using Wilcoxon rank-sum tests and chi-squared tests. 
Next, mixed-effects logistic regression models were fit, first with an empty model with a 
random effect for each hospital, and then by sequentially adjusting for variables from 
each domain in the order described above, which moves from patient-level to hospital-
level factors. This ordering allowed for the separation of patient- and hospital-level 
variables to determine their contributions to interhospital variation in mortality. The 
change in the adjusted variation of 28-day mortality was calculated, moving from one 
model to the next, by examining the median odds ratio for each model. The median 
odds ratio can be interpreted as the difference in odds between a randomly selected 
lower-risk hospital and a randomly selected higher-risk hospital. It can be 
conceptualized as the increased risk that a subject would have if he/she was admitted 
to a higher risk hospital.14,15 Pseudo-R2 values were also calculated for each individual 
domain using Efron’s R2, which is calculated by taking the sum of the squared model 
residuals divided by the total variability in the dependent variable.
Finally, to calculate the contribution of the domains to an individual’s risk of mortality, a 
gradient boosted tree machine learning model was fit using all the variables from each 
domain.16 Ten-fold cross-validation was used to optimize the model’s area under the 
receiver operating characteristic curve. Shapley values were then calculated for each 
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individual patient, which estimate the contribution of each variable for that individual 
patient’s risk of 28-day mortality.17 The individual Shapley values were then combined 
across all patients in the dataset using the mean of their absolute value to determine the 
percent mortality risk explained by each domain. All analyses were performed using 
Stata version 16.1 (StataCorps, College Station, TX) and R version 4.2 (R Foundation 
for Statistical Computing, Vienna, Austria) with the caret, xgboost, and iml packages. A 
two-sided p-value <0.05 denoted statistical significance.
RESULTS
Patient characteristics 
A total of 4,019 patients (median age [IQR] 63 [53-72]; 63% male (n = 2532)) from 70 
hospitals were included in the analysis after exclusion criteria were applied (Figure E1 
and Table E1 in the Supplementary Appendix), and 1,537 (38%) died by 28 days. The 
median number of patients at a given hospital was 34 (IQR 20-79; Figure E2 in the 
Supplementary Appendix). Patients who died were older (median [IQR] 68 [59-76] vs. 
60 [49-68] years), more likely to be male (66% vs. 61%), more likely to be current or 
former smokers (30% vs. 23%), and had higher frequencies of most comorbidities 
compared to those who survived at 28 days (Table 1). Most vital signs and laboratory 
results were significantly different during the first 48 hours of ICU admission between 
those who died compared to those who survived (Table 1). Patients who died were also 
more likely to have received invasive mechanical ventilation (80% vs. 58%) and renal 
replacement therapy (9% vs. 5%) during the first 48 hours of ICU admission. Finally, 
certain medications were more often provided to those who died, such as 
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neuromuscular blocking agents (25% vs. 17%), hydroxychloroquine (63% vs. 59%), and 
corticosteroids (35% vs. 21%) (Table 1).
Hospital-level analysis
Patients who died were admitted to hospitals with a higher percentage of ICU beds 
occupied by COVID-19 patients (48% vs. 31%), a higher percentage of the population 
traveling >45 minutes to work (23% vs. 18%), a lower pre-pandemic ICU occupancy 
rate (69% vs. 74%), lower number of pre-COVID-19 ICU beds (median [IQR] 53 [47-98] 
vs. 98 [54-115]), higher number of COVID-19 cases in the county in the prior 30 days 
(median [IQR] 2,279 [640-7,268] vs. 1,416 [398-4,585]), and lower hospital quality 
scores as compared to patients who survived (Table 2).
Twenty-eight-day mortality varied widely across hospitals, from 0% at the lowest risk 
hospital to 82% at the highest. In the mixed-effects regression model, the median odds 
ratio decreased from 2.06 (95% CI, 1.73-2.37) in the unadjusted model to 1.22 (95% CI, 
1.00-1.38) in the fully adjusted model (Figure 1). This was associated with a change in 
the range of mortality across hospitals from 12-91% (random effects only) to 32-44% 
(fully adjusted model). Model adjustment with variables from the physiology, 
socioeconomic status, and strain domains were associated with the greatest change in 
the median odds ratio (all >0.20 change in the point estimate). The fully adjusted model 
explained nearly all the variability across hospitals (p-value for random effect term=0.73; 
see Table E3 in the Supplementary Appendix for model coefficients). Pseudo-R2 
values for each individual domain demonstrated similar results, with physiology (0.2), 
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demographics (0.11), socioeconomic status (0.10), and strain (0.09) having the highest 
values, followed by quality (0.06) and treatments (0.04).
Patient-level analysis
The Shapley values calculated from the XGBoost model using variables from all the 
domains found that physiology (49%), demographics and comorbidities (20%), hospital 
socioeconomic status (12%), strain (9%), hospital quality (8%), and treatments (3%) all 
contributed to mortality risk (Figure 2). The mean contributions of the individual 
variables in each domain are shown in Figures E3-E8 in the Supplementary 
Appendix. Thus, for patients in the dataset, on average their presenting physiology 
explained half of their quantifiable individual risk of mortality, while external factors such 
as hospital socioeconomic status, hospital capacity and strain, hospital quality, and the 
treatments clinicians provided explained over one-quarter (31%) of their mortality risk. 
Among patient demographics, age had the highest contribution, explaining 12% of the 
mortality risk, while co-morbidities explained 4% of a patient’s mortality risk. Temporal 
trends captured by the “days since study start” variable only explained a small 
percentage of a patient’s mortality risk (1%).
Sensitivity analysis
Performing the analyses using in-hospital mortality (n=3,904 (97.1%) with complete 
hospital follow-up) demonstrated similar results to the main analysis that used 28-day 
mortality (Figures E9 and E10 in the Supplementary Appendix). For example, the 
median odds ratio decreased from 2.10 (95% CI, 1.76-2.41) in the unadjusted model to 
1.18 (95% CI, 1.00-1.36) in the fully adjusted model, and adjustment with variables from 
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the physiology, socioeconomic status, and strain domains were associated with the 
greatest change in the median odds ratio. The ordering and magnitude of the domains 
regarding their contribution to individual risk was also similar. Adding outside hospital 
transfers back into the cohort also demonstrated similar results to the primary analysis 
(Figures E11 and E12 in the Supplementary Appendix).
DISCUSSION
In this multicenter cohort study of 4,019 critically ill adults with COVID-19 admitted to 
ICUs at 70 geographically-diverse hospitals across the United States, we found wide 
variation in 28-day mortality across hospitals. This hospital-level variability was mostly 
explained by differences in socioeconomic status of the hospital population, hospital 
capacity and strain, and presenting ICU physiology. Further, the mortality risk for 
individual patients was largely explained by demographic characteristics and co-
morbidities as well as acute physiology. To our knowledge, this is the first manuscript of 
its kind investigating both hospital- and individual-level contributors to variation in 
mortality from a large, nationally representative cohort of critically ill patients with 
COVID-19. Our results help explain the wide variation in published mortality rates for 
critically ill COVID-19 patients and quantify how different factors contribute to an 
individual patient’s mortality.
Published reports on the outcomes of critically ill COVID-19 patients have shown wide 
variations in mortality. For example, an early report by Arenz et al. reported an in-
hospital mortality rate of 67% for patients admitted to the ICU at one hospital in 
Washington State.18 In contrast, a study by Cummings et al. reported a mortality of 39% 
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in a study from two hospitals in New York City.19 This variability was summarized in a 
recent systematic review by Serafim and colleagues, which reported an in-hospital 
mortality range of 1% to 62%.8 The cause of this variation has been hypothesized to be 
related to various factors such as hospital strain, patient characteristics, and variability 
in treatment practices.5,20-23 
Our findings provide important insights into the reasons for this wide variation in 
hospital-level mortality. We found that hospital socioeconomic status, physiology, and 
hospital strain were the most important factors explaining this variability, while 
treatments provided to patients contributed least. To our knowledge, we are the first to 
show that the socioeconomic status of the community surrounding a hospital is an 
important contributor to hospital-level variability in outcomes in a geographically 
representative sample of critically ill COVID-19 patients. This finding could be due to 
factors related to either the impact of socioeconomic status on the health status of 
individual patients in the study or unobserved variability in the quality of care that 
hospitals provide for a population with a lower socioeconomic status.22,24 Interestingly, 
the most important individual variable from the socioeconomic status domain was the 
percentage of patients at the hospital who traveled >45 minutes to work. This variable 
has been previously used to capture the spatial mismatch hypothesis theory,25,26 which 
relates to discrepancies between the location of low-income neighborhoods and the 
locations of employment opportunities. This variable was also found to be one of the 
most important metrics of social risk in a study investigating hospital ratings and 
neighborhood disadvantage.9 Our findings of increased mortality related to hospital 
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population socioeconomic status suggest that COVID-19 may be exacerbating existing 
healthcare disparities in the US.27
The majority of an individual’s risk of mortality was related to presenting physiology, 
demographics, and pre-existing conditions. Only one-quarter of a patient’s quantifiable 
mortality risk was related to other factors such as hospital capacity and strain, hospital 
socioeconomic status, hospital quality, and treatments. Prior work suggested that the 
number of pre-existing ICU beds is an important predictor of mortality among critically ill 
patients with COVID-19,5 suggesting a correlation between ICU capacity and outcomes.
However, additional factors such as the baseline occupancy rate prior to the pandemic 
and the number of patients with COVID-19 currently admitted to the ICU are important 
to consider when determining the strain on critical care resources. By including these 
variables and other related factors into one domain, we were able to show that strain 
and capacity contribute to both hospital-level variability and individual mortality. This 
contribution to mortality risk may be related to rationing, more aggressive goals of care 
discussions, and treatment of critically ill patients outside the normal ICU or by less 
experienced providers. Hospital quality scores also had some explanatory power, albeit 
less than hospital socioeconomic status or strain. This suggests that the quality of the 
hospital a patient with COVID-19 goes to has a small but measurable effect on their 
outcome, which is consistent with prior work in all hospitalized patients.28
Of all the domains studied, the treatments provided to patients had the least impact on 
hospital-level variability and individual-level mortality risk. This may be explained by the 
fact that few treatments have shown a mortality benefit for critically ill patients with 
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COVID-19.29-32 Notably, the three treatments that contributed the most to improved 
mortality – neuromuscular blockade, aspirin, and Tocilizumab – are all therapies that 
have previously been shown to improve outcomes for patients with COVID-19 or acute 
respiratory distress syndrome.33-35 
This study has several strengths. Our cohort consisted of a geographically diverse 
sample of critically ill adults with COVID-19. We had access to detailed patient 
characteristics, physiology, interventions, and medications during their ICU stay. In 
addition, we were able to link the hospitals where these patients were admitted to 
quality scores and hospital-level socioeconomic status. Furthermore, by linking patients 
to the American Hospital Annual Survey data and time-varying county-level COVID-19 
data, we were able to better quantify capacity and strain. Finally, in addition to standard 
mixed-effects regression models, we also used a state-of-the-art machine learning 
approach to determine the contribution of individual variables to patient mortality.17
This study also has several limitations. First, although we were able to identify variables 
associated with mortality, our study design does not lend itself to inferring causality. In 
addition, our findings only apply to patients admitted to ICU, as we did not have data on 
patients who were critically ill but were not admitted to an ICU (e.g., due to bed rationing 
or goals of care). Furthermore, there may be additional variables that contribute to 
mortality risk that we did not account for in our study. For example, best practices and 
supportive care interventions, such as low tidal volume ventilation for patients with acute 
respiratory distress syndrome, were not collected, nor were other hospital-level factors 
(e.g., teaching status, intensivist coverage, and nurse-to-patient ratios), nor the duration 
of treatments. Similarly, the Shapley values measure only quantifiable mortality that is 
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explained by the variables in the model. It is also possible that some patients were 
discharged alive before day 28 only to die at home soon thereafter (e.g., patients 
discharged to home hospice). Although we verified in 50 patients at six participating 
hospitals that all patients discharged alive before 28 days were still alive at day 28, this 
might not be true at all centers. In addition, the hospital quality data was collected in 
2017, which may not reflect quality of care during the present-day pandemic. Finally, we 
only had hospital-level socioeconomic status available as opposed to individual 
socioeconomic status, so we could not determine whether the impact of this domain 
was related to the socioeconomic status of individual patients or the resources and 
quality that might be associated with hospitals that provide care for patients with varying 
socioeconomic status characteristics.
In conclusion, we found considerable interhospital variation in death among critically ill 
patients with COVID-19. This variability is explained by several domains, including 
hospital socioeconomic status, presenting physiology, and hospital capacity and strain. 
Similar factors contribute to an individual patient’s risk of mortality, with patient-level 
factors (e.g., physiology, demographics, and co-morbidities) explaining most of their 
mortality risk.
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FIGURES AND TABLES
Figure 1. Case-mix Adjusted Probabilities of 28-day Mortality. The graphs illustrate 
the change in interhospital variation in death as each domain is added to the unadjusted 
mixed-effects model (leftmost panel) and ending with the fully adjusted model (rightmost 
panel), which shows that most of the variation in mortality across hospitals can be 
explained by the domains included. The x-axis is hospital ranked by increasing 
probability of death in 28 days, and the y-axis shows the case-mix adjusted probability 
of death in the mixed-effects regression model, with the red dots denoting the point 
estimates and the whiskers denoting the 95% confidence intervals. The median odds 
ratio (OR) and range in mortality are presented for each model.
Abbreviations: Demo = Demographics, SES = Socioeconomic Status
Figure 2. Contributions to 28-Day Mortality Risk Based on Shapley Values. The 
figure illustrates the relative contribution of all variables in each domain based on 
Shapley values calculated from the XGBoost machine learning model (red bars; left y-
axis). The cumulative contribution of the domains, moving from left to right in the figure, 
is shown with the line plot (right y-axis).
 Abbreviations: Demo = Demographics, SES = Socioeconomic Status, Pop = Population
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Table 1. Patient Characteristics at Baseline.





DEMOGRAPHICS & PRE-EXISTING COMORBIDITIES
Demographics    
   Age (years) - median (IQR) 63 (53-72)* 60 (49-68) 68 (59-76)
   Male - n (%) 2532 (63.0)* 1520 (61.2) 1012 (65.8)
   Race- n (%)
      White 1527 (38.0%) 950 (38.3%) 577 (37.5)
      Black 1238 (30.8%) 782 (31.5 %) 456 (29.7%)
      Other 328 (8.2%) 213 (8.6%) 115 (7.5%)
      Unknown/Not Reported 926 (23.0%) 537 (21.6%) 389 (25.3%)
   Ethnicity – n (%)
      Hispanic 954 (23.7%) 601 (24.2%) 353 (23.0%)
      Non-Hispanic 2600 (64.7%) 1604 (64.6%) 996 (64.8%)
      Unknown/Not Reported 465 (11.6%) 277 (11.2%) 188 (12.2%)
   Current or Former Smoker - n (%) 1039 (25.9)* 581 (23.4) 458 (29.8)
   Body Mass Index kg/m² - median (IQR) 30.2 (26.3-35.5)* 30.6 (26.5-35.9) 29.7 (26.0-34.9)
Pre-existing Comorbidities - n (%)
   Active Cancer 190 (4.7)* 80 (3.2) 110 (7.2)
   Congestive Heart Failure 425 (10.6)* 224 (9.0) 201 (13.1)
   Chronic Obstructive Pulmonary Disease 356 (8.9)* 175 (7.1) 181 (11.8)
   Coronary Artery Disease 567 (14.1)* 277 (11.2) 290 (18.9)
   Diabetes 1713 (42.6)* 972 (39.2) 741 (48.2)
   End-Stage Renal Disease 153 (3.8)* 79 (3.2) 74 (4.8)
   Hypertension 2476 (61.6)* 1398 (56.3) 1078 (70.1)
PHYSIOLOGY
Vital Signs a
   Altered Mental Status - n (%) 997 (24.8)* 420 (16.9) 577 (37.5)
   Heart Rate (beats/min) - median (IQR) 105 (91-120)* 103 (90-118) 109 (93-125)
   Respiratory Rate (beats/min) - median (IQR) 32 (26-39)* 32 (26-39) 31 (26-38)
   Systolic Blood Pressure (mm Hg) - median (IQR) 97 (85-111)* 99 (88-112) 94 (82-109)
  Temperature (°C) - median (IQR) 37.9 (37.2-38.8)* 38.0 (37.2-38.8) 37.8 (37.1-38.7)
Labs b
  Arterial pH – median (IQR) 7.3 (7.3-7.4)* 7.4 (7.3-7.4) 7.3 (7.2-7.4)
   Aspartate aminotransferase (U/L) – median (IQR) 60 (39-86)* 56 (37-79) 67 (42-105)
   Creatinine (mg/dl) - median (IQR) 1.2 (0.9-2.1)* 1.1 (0.8-1.6) 1.6 (1.1-2.9)
   C-reactive protein (mg/L) - median (IQR) 173 (115-238)* 168 (108-229) 185 (127-250)
   D-dimer (ng/mL) - median (IQR) 2340 (1015-6135)* 2024 (825-4340) 3841 (1593-9305)
   Ferritin (ng/ml) - median (IQR) 1291 (661-2214)* 1177 (622-1933) 1588 (776-2682)
   High Troponin Indicator c - n (%) 1769 (44.0)* 820 (33.0) 949 (61.7)
   Lactate (mmol/L) - median (IQR) 1.7 (1.3-2.4)* 1.6 (1.3-2.1) 2.0 (1.4-2.9)
   Lymphocytes (%) - median (IQR) 8.9 (5.4-13.3)* 10.0 (6.4-14.6) 7.1 (4.0-11.1)
   Procalcitonin a (ng/ml) - median (IQR)¹ 1.3 (0.2-4.6)* 0.8 (0.2-2.3) 1.4 (0.5-8.0)
   Sodium a (mEq/L) - median (IQR)¹ 137 (134-140)* 136 (134-139) 137 (134-141)
   Urine Output (mL) - median (IQR) 716 (436-1000)* 792 (550-1050) 579 (300-875)
   White Blood Cell Count (per mm³) - median (IQR) 9.6 (6.8-13.3)* 9.0 (6.5-12.1) 10.6 (7.6-15.1)
Severity of Illness b
   PaO2:FiO2 (P/F) Ratio d (mm Hg) - median (IQR) 131 (102-158)* 135 (112-159) 123 (86-155)
   Invasive Mechanical Ventilation - n (%) 2681 (66.7)* 1449 (58.4) 1232 (80.2)
   Renal Replacement Therapy e- n (%) 258 (6.4)* 118 (4.8) 140 (9.1)
   Vasopressors f - n (%)
      One 1367 (34.0)* 790 (31.8) 577 (37.5)
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   Two or more 648 (16.1)* 282 (11.4) 366 (23.8)
TREATMENTS b - n (%)
   Aspirin 696 (17.3)* 389 (15.7) 307 (20.0)
   Azithromycin 2003 (49.8)* 1270 (51.2) 733 (47.7)
   Hydroxychloroquine 2423 (60.3)* 1457 (58.7) 966 (62.8)
   Neuromuscular blockade 812 (20.2)* 428 (17.2) 384 (25.0)
   Prone positioning 1087 (27.0) 663 (26.7) 424 (27.6)
   Remdesivir 238 (5.9)* 168 (6.8) 70 (4.6)
   Statin 913 (22.7) 553 (22.3) 360 (23.4)
   Corticosteroid 1057 (26.3)* 522 (21.0) 535 (34.8)
   Tocilizumab 497 (12.4)* 331 (13.3) 166 (10.8)
   Vitamin  C 281 (7.0)* 148 (6.0) 133 (8.7)
Table 1 Legend. 
*P-value <0.05 for difference between survivors and non-survivors (Wilcoxon rank sum test for continuous variables and chi-
squared for categorical)
Data regarding troponin were missing for 2544 (63%).
Data regarding PaO2:FiO2 were missing for 1576 (39%).
Data regarding PEEP day 1 were missing for 1513 (38%).
Data regarding procalcitonin were missing for 1455 (36%).
Data regarding D-dimer were missing for 1233 (31%)
Data regarding urine output were missing for 1210 (30%).
Data regarding lactate were missing for 1198 (30%)
Data regarding ferritin were missing for 1054 (26%).
Data regarding CRP were missing for 926 (23%). 
Data regarding arterial pH were missing for 902 (22%).
Data regarding smoking status were missing for 745 (19%). 
Data regarding lymphocytes were missing for 36 (11%). 
Data regarding AST were missing for 353 (9%). 
Data regarding mental status were missing for 220 (5%).
Data regarding PEEP day 2 were missing for 163 (4%).
Data form BMI were missing for 152 (4%). 
Data regarding WBC was missing for 77 (2%).
Data regarding creatinine were missing for 70 (2%).
Data regarding sodium were missing for 24 (<1%)
Missing data were imputed using bagImpute and are included in the table
a Collected upon ICU admission
b Worst value or if occurred anytime during day 1-2 in the ICU
c Troponin T or I > the 99th percentile upper reference limit of normal for that lab
d Refers to the PaO2:FiO2 ratio and was only recorded in patients receiving invasive mechanical ventilation. Other values imputed. 
e Received renal replacement therapy for acute or chronic renal failure
f Included phenylephrine hydrochloride, epinephrine, norepinephrine bitartrate, vasopressin, dopamine hydrochloride, dobutamine, 
and milrinone
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Table 2. Hospital Characteristics for Patients Included in the Study.





SOCIOECONOMICS OF HOSPITAL POP
   % of Population for whom Commute to Work takes > 45 
     min– median (IQR) 18.3 (12.9-25.5)* 17.8 (11.8-21.0) 23.4 (15.9-29.3)
   % of Households Speaking English Only– median (IQR) 72.6 (62.7-80.9)* 72.9 (64.3-82.4) 70.9 (61.8-78.9)
   % of Population Uninsured– median (IQR) 9.1 (5.7-13.0) 9.0 (5.7-13.0) 10.0 (5.6-13.0)
   % of Population who are Black– median (IQR) 15.2 (8.9-27.0) 16.2 (9.7-27.0) 15.2 (8.3-28.0)
   % of Population who are Dual Eligible– median (IQR) 2.5 (1.3-3.3) 2.6 (1.5-3.2) 2.3 (1.3-3.3)
   % of Population with High School Diploma– median (IQR) 88.0 (83.3-93.5) 88.1 (83.2-92.3) 87.4 (83.3-94.5)
   % of the Population who are Unemployed– median (IQR) 7.3 (5.6-9.7) 7.3 (5.6-9.2) 7.3 (5.3-9.7)
   % Single Parent Households– median (IQR) 17.4 (12.8-22.1)* 17.0 (12.8-22.1) 17.5 (13.1-22.2)
   Mean Household Size– median (IQR) 2.5 (2.3-2.8)* 2.5 (2.2-2.7) 2.7 (2.4-2.9)










   Metro Area – n (%) 3,534 (87.9) 2,124 (85.6) 1,410 (91.7)
HOSPITAL STRAIN – median (IQR)
   % of Hospital ICU Beds w/ STOP COVID Patients a 37.5 (14.4-69.6)* 30.6 (12.3-53.8) 48.2 (19.0-104.3)





   ICU Occupancy Rate 75.0 (58.7-83.2)* 76.4 (63.2-84.2) 69.3 (54.2-82.1)
   # Hospital Medical-Surgical Beds 510 (329-718)* 555 (358-733) 437 (266-691)
   Hospital Total Occupancy Rate 77.3 (69.5-84.6)* 79.5 (69.6-84.6) 74.6 (66.8-84.5)
   # of  ICU Beds pre-COVID-19 88 (48-112)* 98 (54-115) 53 (47-98)
   Total # of County COVID Cases in the 30 days prior to   
    Admission a 1,743 (475-5,845)* 1,416 (398-4,585) 2,279 (640-7,268)
   Total # of Hospital Beds 682 (448-1,006)* 794 (522-1,006) 610 (355-937)
   Total # of Hospital Beds in the County 3,411 (2,286-5,326)* 3,657 (2,156-5,344) 2,768 (2,310-5,069)
   In COVID ICU or surge - n (%) 3047 (76) 1879 (76) 1168 (76)
HOSPITAL QUALITY – median (IQR)
   Standardized Outcomes Mortality Score 0.9 (0.4-1.9)* 1.0 (0.4-2.0) 0.5 (0.4-1.4)
   Standardized Outcomes Readmission Score -0.9 (-2.0--0.4)* -0.9 (-1.7--0.4) -0.9 (-2.2--0.4)
   Standardized Outcomes Safety Score -0.1 (-1.1-0.6)* -0.1 (-1.0-0.7) -0.3 (-1.7-0.2)
   Standardized Patient Experience Score -0.3 (-0.7-0.4)* 0.0 (-0.6-0.4) -0.6 (-0.9-0.2)
   Standardized Process Effect Score -0.1 (-0.8-0.6)* 0.1 (-0.5-0.6) -0.3 (-1.4-0.5)
   Standardized Process Time Score -1.6 (-2.8--0.8) -1.6 (-2.7--0.9) -1.6 (-2.8--0.4)
   Study Day 30 (23-40) 30 (23-41) 30 (23-39)
HOSPITAL TREATMENT INTENSITY – n (%)
   % patients vented w/ P/F < 150 receiving more intense 
therapies 60 (47-67)* 57 (47-67) 63 (43-67)
Table 2 Legend.
*P-value <0.05 for difference between survivors and non-survivors (Wilcoxon rank sum test for continuous variables and chi-
squared for categorical)
a Time-varying based on the date of patient admission.
Data regarding ICU occupancy rate was missing for 97 (2%)
Missing data were imputed using bagImpute and are included in the table
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Figure 1. Case-mix Adjusted Probabilities of 28-day Mortality. The graphs illustrate the change in 
interhospital variation in death as each domain is added to the unadjusted mixed-effects model (leftmost 
panel) and ending with the fully adjusted model (rightmost panel), which shows that most of the variation in 
mortality across hospitals can be explained by the domains included. The x-axis is hospital ranked by 
increasing probability of death in 28 days, and the y-axis shows the case-mix adjusted probability of death 
in the mixed-effects regression model, with the red dots denoting the point estimates and the whiskers 
denoting the 95% confidence intervals. The median odds ratio (OR) and range in mortality are presented for 
each model. Abbreviations: Demo = Demographics, SES = Socioeconomic Status 
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Figure 2. Contributions to 28-Day Mortality Risk Based on Shapley Values. The figure illustrates the relative 
contribution of all variables in each domain based on Shapley values calculated from the XGBoost machine 
learning model (red bars; left y-axis). The cumulative contribution of the domains, moving from left to right 
in the figure, is shown with the line plot (right y-axis). Abbreviations: Demo = Demographics, SES = 
Socioeconomic Status, Pop = Population 
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O. Boateng, Meghan Lee, Ian A. Strohbehn, Jiahua Li, Ariel L. Mueller
ProMedica Health System: Roberta Redfern,* Nicholas S. Cairl, Gabriel Naimy, Abeer Abu-Saif, Danyell Hall, Laura Bickley
Renown Health: Chris Rowan*, Farah Madhai-Lovely*
Rush University Medical Center: Vasil Peev*, Jochen Reiser, John J. Byun, Andrew Vissing, Esha M. Kapania, Zoe Post, Nilam 
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Beutler; Santa Monica-UCLA Medical Center – Carl E. Schulze
University of California-San Diego Medical Center: Etienne Macedo*, Harin Rhee
University of California-San Francisco Medical Center: Kathleen D. Liu*, Vasantha K. Jotwani
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University of Illinois Hospital and Health Sciences System: Stephanie M. Toth-Manikowski*, Min J. Joo*, James P. Lash
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University of Oklahoma Health Sciences Center: Brent R. Brown*
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Table E1. STOP-COVID Sites and Hospitals Included in this Study
Site Hospitals
Northeast
Beth Israel Deaconess Medical Center Beth Israel Deaconess Medical Center
Brigham and Women’s Faulkner Hospital Brigham and Women’s Faulkner Hospital
Brigham and Women's Hospital Brigham and Women's Hospital
Cooper University HospitalCooper University Health Care Inspira Medical Center Vineland 
Hackensack Meridian Health Hackensack University Medical 
Center Hackensack Meridian Health Pascack Valley Medical
Hackensack Mountainside Hospital Hackensack-UMC Mountainside Hospital
Johns Hopkins HospitalJohns Hopkins Hospital Johns Hopkins Bayview Medical Center
Kings County Hospital Center Kings County Hospital Center
Massachusetts General Hospital Massachusetts General Hospital
MedStar Georgetown University Hospital MedStar Georgetown University Hospital
Montefiore Medical Center Montefiore Medical Center
Mount Sinai Mount Sinai
Newton Wellesley Hospital Newton Wellesley Hospital
New York-Presbyterian Queens Hospital New York-Presbyterian Queens Hospital
New York-Presbyterian/Weill Cornell Medical Center New York-Presbyterian/Weill Cornell Medical Center
New York University Langone Hospital New York University Langone Hospital
Rutgers/New Jersey Medical School University Hospital
Rutgers/Robert Wood Johnson Medical School Robert Wood Johnson Medical School
Temple University Hospital Temple University Hospital
Kennedy University Hospital – Stratford DivisionThomas Jefferson University Hospital Thomas Jefferson University Hospital 
Tufts Medical CenterTufts Medical Center Lowell General Hospital
University Medical Center of Princeton at Plainsboro
Penn Presbyterian Medical Center University of Pennsylvania Health System
Hospital of University of Pennsylvania
University of Pittsburgh Medical Center UPMC Passavant
Westchester Medical Center Westchester Medical Center
Yale University Medical Center Yale-New Haven Hospital
South
Baylor College of Medicine, Houston Harris Health System
Baylor University Medical Center/Baylor Scott White and 
Health Baylor University Medical Center 
Duke University Medical Center Duke University Medical Center
Memphis VA Medical Center/ Methodist University Hospital Methodist Healthcare Memphis Hospitals
Ochsner Medical Center Ochsner Medical Center
Tulane Medical Center Tulane Medical Center
University of Alabama-Birmingham Hospital University of Alabama Hospital
University of Florida Health-Gainesville UF Health Shands Hospital
University of North Carolina Hospitals University of North Carolina Hospitals
University of Texas Southwestern Medical Center Parkland Health and Hospital System
University of Virginia Health System University of Virginia Medical Center
Midwest
Barnes-Jewish Hospital Barnes-Jewish Hospital
Cook County Health John H Stroger Jr Hospital
Froedtert Hospital Froedtert Memorial Lutheran Hospital
Indiana University Health Methodist Hospital Indiana University Health
Mayo Clinic, Rochester Minnesota Mayo Clinic, Rochester Minnesota
Northwestern Memorial Hospital Northwestern Memorial Hospital
Bay Park Community Hospital
Promedica Monroe Regional HospitalPromedica Health System
Toledo Hospital 
Rush University Medical Center Rush University Medical Center
UH Cleveland Medical CenterUniversity Hospitals Cleveland Medical Center University Hospitals Ahuja Medical Center 
University of Chicago Medical Center University of Chicago Medical Center
University of Illinois Hospital and Health Sciences System University of Illinois Hospital and Health Sciences System 
University of Kentucky Hospital University of Kentucky Hospital
University of Michigan Hospital University of Michigan Hospital
West
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Loma Linda University Medical Center Loma Linda University Medical Center
Mayo Clinic, Arizona Mayo Clinic, Arizona
Renown Health Renown Regional Medical Center
Stanford Healthcare Stanford Healthcare
University of California-Davis Medical Center University of California-Davis Medical Center
University of California-Los Angeles Medical Center Ronald Reagan UCLA Medical Center
University of California-San Diego Medical Center UC San Diego Health Hillcrest - Hillcrest Med Ctr
University of California-San Francisco Medical Center UCSF Medical Center
UCHealth University of Colorado University of Colorado Hospital Authority
University Medical Center of Southern Nevada University Medical Center
Harborview Medical CenterUniversity of Washington Medical Center University of Washington Medical Ctr
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Table E2. Variable Descriptions and Sources
Variable Description/Collection Notes Source
Vitals
   Altered Mental Status
   Highest Heart Rate (beats/min)
   Highest Respiratory Rate (beats/min)
   Lowest Systolic Blood Pressure (mm Hg)
   Max Temperature (°C)
Collected on day 1 of ICU admission
Labs
   Arterial pH
   Aspartate aminotransferase - AST (U/L)
C-reactive protein - CRP (mg/L)
   Creatinine (mg/dl)
D-dimer (ng/mL)
   Ferritin (ng/ml)
   High Troponin Indicator
   Lactate (mmol/L)
   Lymphocytes (%)
   Procalcitonin (ng/ml)
   Sodium (mEq/L)
   Urine Output (mL)
   White Blood Cell Count (per mm3)
Collected once a day for the first 14 days in the ICU – 
used worst value during days 1-2 in the ICU (sodium and 
procalcitonin were recorded on day 1 only)
Severity of Illness
   P/F Ratio (mm Hg)
   Ventilator Status
   PEEP
Collected only on patients receiving invasive mechanical 
ventilation with an arterial blood gas available
   Number of Vasopressors Maximum number of vasopressors required each day
   Renal Replacement Therapy CRRT, intermittent hemodialysis, peritoneal dialysis, other
Demographics
   Age (years)
   Body Mass Index (BMI)
   Current or Former Smoker
Per chart review; does not include vaping or smoking of 
non-tobacco products. Non-smoker, former smoker, 
current smoker
   Race and Ethnicity 
   Sex (Male)
Pre-existing Comorbidities
   Active Cancer
   Congestive Heart Failure
   Chronic Obstructive Pulmonary Disease
   (COPD)
   Coronary Artery Disease
   Diabetes
   End Stage Renal Disease (ESRD)
   Hypertension
Per manual chart review of the electronic health record.
Treatments
   Aspirin
   Azithromycin
   Corticosteroid
   Hydroxychloroquine
   Neuromuscular Blockade
   Prone positioning
   Remdesivir
   Statin
   Tocilizumab
   Vitamin C (IV or PO)
Date recorded for day of treatment initiation. Indicated as 
present if date of initiation was either before ICU 
admission or on ICU days 1 or 2.
STOP COVID dataset
   Hospital Level Treatment Intensity
Percentage of mechanically ventilated patients with a 
PaO2/FiO2 ratio<150 who were treated with 
extracorporeal membrane oxygenation, inhaled pulmonary 
vasodilators, tocilizumab, prone positioning, or 
neuromuscular blockade.
SES of Hospital Population
   % of Households Speaking English Only
   % of Population for whom Work Commute 
    takes > 45 min
   % of Population Uninsured
   % of Population who are Black
   % of Population who are Dual Eligible
Geographic catchment regions were calculated for each 
hospital based on the number of hospital beds. American 
Community Survey results where then combined across 
the closest block groups containing this population.
American Community Survey 2015 summarized 
over each hospital’s local geographic catchment 
area.
US Census Bureau. American Community 
Survey 5-Year Estimates. 2015. Available at: 
https://www.nhgis.org. Accessed March 22, 
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   % of Population with  High School Diploma
   % of the Population who are Unemployed
   % Single Parent Households
   Mean Household Size
   Mean Median Home Value
   Mean Median Income
2018.
   Metro Area




   # of COVID Cases in the County in the last 
   30 Days 




   # of pre-COVID ICU Beds
   % of Hospital ICU Beds w/ STOP COVID    
   Patients
Calculated using the total number of ICU beds in the 
hospital prior to the pandemic in the denominator and the 
current number of hospitalized COVID patients in the 
numerator.
   COVID-specific or Surge ICU Whether an ICU was a COVID-specific ICU or surge ICU.
STOP COVID Dataset
   # of Hospital Medical-Surgical Beds
   Hospital Total Occupancy Rate
   Total # of Hospital Beds
   Total # of Hospital Beds in the County 
From the 2018 AHA Annual Surveys of Hospitals and U.S. 
Census Bureau population data – published Jan 31,2020




   ICU Occupancy Rate
Healthcare Cost Report Information System, a 
Centers for Medicare and Medicaid Services 
dataset composed of the cost reports submitted 
by Medicare-certified hospitals
   County Population





   Standardized Outcomes Mortality Score
   Standardized Outcomes Readmission Score
   Standardized Outcomes Safety Score
   Standardized Patient Experience Score
   Standardized Process Effect Score
   Standardized Process Time Score
Up to 57 quality metrics were assessed and combined into 
7 quality group scores. These then determine the star 
rating from 1-5 used by Medicare. We use 6 of the 7 score 
components (efficiency excluded due to multicolinearity). 
Score were standardized across all hospitals in the 
Medicare Compare dataset.
Medicare Hospital Compare dataset
US Centers for Medicare Medicaid Services. 
December 2017 Hospital Compare. . Available 
at: 
www.medicare.gov/hospitalcompare/search.htm
l. Accessed August 14, 2018.
   Study Day Days since study start STOP COVID Dataset
Other
   Death Discharged, follow-up 28 + days, or death before day 28
   Hospital Name Used for linking to Medicare provider ID for hospital data STOP COVID Dataset
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Table E3. Final Mixed-Effects Model Coefficient Odds Ratios
Variable Odds Ratio (95% CI)
PHYSIOLOGY
Vitals
   Altered Mental Status 1.566 (1.287 - 1.906)
   Highest Heart Rate (beats/min) 1.004 (1.000 - 1.008)
   Highest Respiratory Rate (beats/min) 0.997 (0.988 - 1.005)
   Lowest Systolic Blood Pressure (mm Hg) 0.999 (0.995 - 1.003)
   Max Temperature (°C) 0.980 (0.900 - 1.067)
Labs
   Arterial pH 0.206 (0.079 - 0.540)
   Aspartate aminotransferase - AST (U/L) 1.000 (1.000 - 1.001)
   C-reactive protein - CRP (mg/L) 1.000 (0.999 - 1.001)
   Creatinine (mg/dl) 1.098 (1.041 - 1.159)
   D-dimer (ng/mL) 1.000 (1.000 - 1.000)
   Ferritin (ng/ml) 1.000 (1.000 - 1.000)
   High Troponin Indicator 1.238 (1.022 - 1.499)
   Lactate (mmol/L) 1.151 (1.086 - 1.220)
   Lymphocytes (%) 0.997 (0.987 - 1.007)
   Procalcitonin (ng/ml) 0.997 (0.991 - 1.002)
   Sodium (mEq/L) 1.019 (1.005 - 1.034)
   Urine Output (mL) 1.000 (1.000 - 1.000)
   White Blood Cell Count (per mm3) 0.996 (0.982 - 1.010)
Severity of Illness
   P/F Ratio (mm Hg) 0.998 (0.997 - 0.999)
   Ventilator Status Day 1 (ref = not ventilated)
      Mechanical Ventilator and PEEP 5 or less 1.604 (0.970 - 2.655)
      Mechanical Ventilator and PEEP 6-10 2.493 (1.685 - 3.689)
      Mechanical Ventilator and PEEP 11-15 2.026 (1.405 - 2.922)
      Mechanical Ventilator and PEEP > 15 2.012 (1.289 - 3.138)
      BiPAP/CPAP/HFNC 2.227 (1.626 - 3.051)
   Mechanical Ventilator Day 2 0.798 (0.490 - 1.300)
   PEEP Day 2 1.036 (1.001 - 1.072)
   Number of Vasopressors (ref = none)
      One 1.087 (0.873 - 1.353)
      Two or more 1.330 (1.003 - 1.765)
   Renal Replacement Therapy 1.054 (0.699 - 1.590)
DEMOGRAPHICS & PRE-EXISTING COMORBIDITIES
Demographics
   Age (years) 1.049 (1.041 - 1.057)
   Body Mass Index (BMI) 1.017 (1.006 - 1.029)
   Smoker Ever 1.225 (1.013 - 1.482)
   Race/Ethnicity (ref = Non-Hispanic White)
      Hispanic 1.055 (0.828 - 1.343)
      Non-Hispanic Black 0.773 (0.614 - 0.972)
      Unknown/Other 0.926 (0.724 - 1.184)
   Sex (Male) 1.447 (1.214 - 1.725)
Pre-existing Comorbidities
   Active Cancer 2.121 (1.482 - 3.035)
   Congestive Heart Failure 1.204 (0.927 - 1.564)
   Chronic Obstructive Pulmonary Disease (COPD) 1.381 (1.045 - 1.825)
   Coronary Artery Disease 1.113 (0.880 - 1.408)
   Diabetes 1.156 (0.976 - 1.370)
   End Stage Renal Disease (ESRD) 0.795 (0.461 - 1.369)
   Hypertension 1.034 (0.858 - 1.246)
TREATMENTS
   Aspirin 1.246 (0.994 - 1.564)
   Azithromycin 1.031 (0.865 - 1.229)
   Corticosteroid 1.251 (1.022 - 1.531)
   Hydroxychloroquine 0.987 (0.809 - 1.203)
   Neuromuscular Blockade 1.389 (1.120 - 1.723)
   Prone positioning 0.951 (0.776 - 1.165)
   Remdesivir 1.235 (0.858 - 1.779)
   Statin 0.983 (0.798 - 1.211)
   Tocilizumab 0.733 (0.565 - 0.951)
   Vitamin C (IV or PO) 0.825 (0.592 - 1.149)
   Hospital Level Treatment Intensity 0.998 (0.992 - 1.005)
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SES OF HOSPITAL POPULATION
   % of Households Speaking English Only 0.969 (0.947 - 0.993)
   % of Population for whom Commute to Work takes    
    >45 min
1.021 (0.996 - 1.047)
   % of Population Uninsured 1.012 (0.943 - 1.085)
   % of Population who are Black 1.010 (0.988 - 1.032)
   % of Population who are Dual Eligible 0.841 (0.629 - 1.123)
   % of Population with  High School Diploma 1.083 (1.002 - 1.171)
   % of the Population who are Unemployed 1.008 (0.928 - 1.095)
   % Single Parent Households 0.992 (0.907 - 1.085)
   Mean Household Size 1.563 (0.454 - 5.384)
   Mean Median Home Value 1.000 (1.000 - 1.000)
   Mean Median Income 1.000 (1.000 - 1.000)
   Metro Area 0.991 (0.590 - 1.665)
HOSPITAL STRAIN
   # of COVID Cases in the County in the last 30 
   Days a
0.998 (0.994 - 1.003)
   # of pre-COVID ICU Beds (ref > 100)
      51-100 1.030 (0.757 - 1.402)
      ≤ 50 1.605 (0.946 - 2.723)
   % of Hospital ICU Beds w/ STOP COVID Patients 1.021 (0.789 - 1.322)
   # of Hospital Medical Surgical Beds 1.002 (1.000 - 1.004)
   Hospital Total Occupancy Rate 0.978 (0.963 - 0.993)
   Total # of Hospital Beds 0.999 (0.997 - 1.000)
   Total # of Hospital Beds in the County a 1.004 (0.994 - 1.013)
   ICU Occupancy Rate 0.999 (0.989 - 1.010)
   Indictor for COVID ICU or Surge 1.162 (0.938 - 1.439)
HOSPITAL QUALITY
   Standardized Outcomes Mortality Score 0.680 (0.579 - 0.799)
   Standardized Outcomes Readmission Score 0.969 (0.824 - 1.140)
   Standardized Outcomes Safety Score 0.983 (0.859 - 1.124)
   Standardized Patient Experience Score 0.976 (0.766 - 1.245)
   Standardized Process Effect Score 0.962 (0.800 - 1.157)
   Standardized Process Time Score 0.977 (0.835 - 1.143)
   Study day 0.996 (0.988 - 1.005)
OTHER
   Intercept 1.120 (0 - 97905)
   Hospital RE 0.043 (0.008 - 0.222)
Table E3. Legend
a  scaled to county pop (note in XGBoost model did not scale and included county population as its own variable due to the 
interaction mechanisms in XGBoost)
Abbreviations: ICU = intensive care unit, RE = random effect
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Figure E1. Study CONSORT Diagram
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Figure E2. Histogram of the Number of Patients at each Hospital.
Abbreviations: # = Number
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Figure E3. Shapley Value Percentage Contributions to the XGBoost Model Prediction 
within the Physiology Domain. The figure shows the sum of the percent contributions of each 
variable in the physiology domain (vitals, labs, and ventilation).
Abbreviations: WBC = white blood cell; AST = Aspartate transaminase, SBP = Systolic blood 
pressure, CRP = C-reactive Protein, Mech = Mechanical, Vent = Ventilation 
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Figure E4. Shapley Value Percentage Contributions to the XGBoost Model Prediction 
within the Demographics and Comorbidities Domain. The figure shows the sum of the 
percent contributions of each variable in the demographics and comorbidities domain.
Abbreviations: BMI = Body mass index, COPD = Chronic obstructive pulmonary disease; ESRD 
= End stage renal disease
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Figure E5. Shapley Value Percentage Contributions to the XGBoost Model Prediction 
within the Socioeconomics of the Hospital Population Domain. The figure shows the sum 
of the percent contributions of each variable in the socioeconomics of hospital population 
domain.
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Figure E6. Shapley Value Percentage Contributions to the XGBoost Model Prediction 
within the Hospital Strain Domain. The figure shows the sum of the percent contributions of 
each variable in the hospital strain domain.
Abbreviations: # = number, ICU = intensive care unit
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Figure E7. Shapley Value Percentage Contributions to the XGBoost Model Prediction 
within the Hospital Quality Domain. The figure shows the sum of the percent contributions of 
each variable in the hospital quality domain.
Abbreviations: Std = Standardized
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Figure E8. Shapley Value Percentage Contributions to the XGBoost Model Prediction 
within the Treatment Domain. The figure shows the sum of the percent contributions of each 
variable in the treatment domain.
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Figure E9. Case-mix Adjusted Probabilities of In-Hospital Mortality. The graphs illustrate the change in interhospital variation in 
death as each domain is added to the unadjusted mixed-effects model (leftmost panel) and ending with the fully adjusted model 
(rightmost panel), which shows that most of the variation in mortality across hospitals can be explained by the domains included. The 
x-axis is hospital ranked by increasing probability of in-hospital death, and the y-axis shows the case-mix adjusted probability of 
death in the mixed-effects regression model, with the red dots denoting the point estimates and the whiskers denoting the 95% 
confidence intervals. The median odds ratio (OR) and range in mortality are presented for each model.
Abbreviations: Demo = Demographics, SES = Socioeconomic Status
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Figure E10. Contributions to In-Hospital Mortality Risk Based on Shapley Values. The 
figure illustrates the relative contribution of all variables in each domain based on Shapley 
values calculated from the XGBoost machine learning model (red bars; left y-axis). The 
cumulative contribution of the domains, moving from left to right in the figure, is shown with the 
line plot (right y-axis).
Abbreviations: Demo = Demographics, SES = Socioeconomic Status, Pop = Population
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Figure E11. Case-mix Adjusted Probabilities of 28-Day Mortality with Transfer Patients included. The graphs illustrate the 
change in interhospital variation in death as each domain is added to the unadjusted mixed-effects model (leftmost panel) and ending 
with the fully adjusted model (rightmost panel), which shows that most of the variation in mortality across hospitals can be explained 
by the domains included. The x-axis is hospital ranked by increasing probability of in-hospital death, and the y-axis shows the case-
mix adjusted probability of death in the mixed-effects regression model, with the red dots denoting the point estimates and the 
whiskers denoting the 95% confidence intervals. The median odds ratio (OR) and range in mortality are presented for each model.
Abbreviations: Demo = Demographics, SES = Socioeconomic Status
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Figure E12. Contributions to 28-Day Mortality Risk with Transfer Patients included Based 
on Shapley Values. The figure illustrates the relative contribution of all variables in each 
domain based on Shapley values calculated from the XGBoost machine learning model (red 
bars; left y-axis). The cumulative contribution of the domains, moving from left to right in the 
figure, is shown with the line plot (right y-axis).
Abbreviations: Demo = Demographics, SES = Socioeconomic Status, Pop = Population
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